Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer

M. Widschwendter, M. Zikan, B. Wahl, H. Lempiäinen, T. Paprotka, I. Evans, A. Jones, S. Ghazali, D. Reisel, J. Eichner, T. Rujan, Z. Yang, AE. Teschendorff, A. Ryan, D. Cibula, U. Menon, T. Wittenberger,

. 2017 ; 9 (1) : 116. [pub] 20171222

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu hodnotící studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001023

BACKGROUND: Despite a myriad of attempts in the last three decades to diagnose ovarian cancer (OC) earlier, this clinical aim still remains a significant challenge. Aberrant methylation patterns of linked CpGs analyzed in DNA fragments shed by cancers into the bloodstream (i.e. cell-free DNA) can provide highly specific signals indicating cancer presence. METHODS: We analyzed 699 cancerous and non-cancerous tissues using a methylation array or reduced representation bisulfite sequencing to discover the most specific OC methylation patterns. A three-DNA-methylation-serum-marker panel was developed using targeted ultra-high coverage bisulfite sequencing in 151 women and validated in 250 women with various conditions, particularly in those associated with high CA125 levels (endometriosis and other benign pelvic masses), serial samples from 25 patients undergoing neoadjuvant chemotherapy, and a nested case control study of 172 UKCTOCS control arm participants which included serum samples up to two years before OC diagnosis. RESULTS: The cell-free DNA amount and average fragment size in the serum samples was up to ten times higher than average published values (based on samples that were immediately processed) due to leakage of DNA from white blood cells owing to delayed time to serum separation. Despite this, the marker panel discriminated high grade serous OC patients from healthy women or patients with a benign pelvic mass with specificity/sensitivity of 90.7% (95% confidence interval [CI] = 84.3-94.8%) and 41.4% (95% CI = 24.1-60.9%), respectively. Levels of all three markers plummeted after exposure to chemotherapy and correctly identified 78% and 86% responders and non-responders (Fisher's exact test, p = 0.04), respectively, which was superior to a CA125 cut-off of 35 IU/mL (20% and 75%). 57.9% (95% CI 34.0-78.9%) of women who developed OC within two years of sample collection were identified with a specificity of 88.1% (95% CI = 77.3-94.3%). Sensitivity and specificity improved further when specifically analyzing CA125 negative samples only (63.6% and 87.5%, respectively). CONCLUSIONS: Our data suggest that DNA methylation patterns in cell-free DNA have the potential to detect a proportion of OCs up to two years in advance of diagnosis and may potentially guide personalized treatment. The prospective use of novel collection vials, which stabilize blood cells and reduce background DNA contamination in serum/plasma samples, will facilitate clinical implementation of liquid biopsy analyses.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001023
003      
CZ-PrNML
005      
20190118124106.0
007      
ta
008      
190107s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13073-017-0500-7 $2 doi
035    __
$a (PubMed)29268796
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Widschwendter, Martin $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, Room 340, 74 Huntley Street, London, WC1E 6AU, UK. M.Widschwendter@ucl.ac.uk.
245    14
$a The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer / $c M. Widschwendter, M. Zikan, B. Wahl, H. Lempiäinen, T. Paprotka, I. Evans, A. Jones, S. Ghazali, D. Reisel, J. Eichner, T. Rujan, Z. Yang, AE. Teschendorff, A. Ryan, D. Cibula, U. Menon, T. Wittenberger,
520    9_
$a BACKGROUND: Despite a myriad of attempts in the last three decades to diagnose ovarian cancer (OC) earlier, this clinical aim still remains a significant challenge. Aberrant methylation patterns of linked CpGs analyzed in DNA fragments shed by cancers into the bloodstream (i.e. cell-free DNA) can provide highly specific signals indicating cancer presence. METHODS: We analyzed 699 cancerous and non-cancerous tissues using a methylation array or reduced representation bisulfite sequencing to discover the most specific OC methylation patterns. A three-DNA-methylation-serum-marker panel was developed using targeted ultra-high coverage bisulfite sequencing in 151 women and validated in 250 women with various conditions, particularly in those associated with high CA125 levels (endometriosis and other benign pelvic masses), serial samples from 25 patients undergoing neoadjuvant chemotherapy, and a nested case control study of 172 UKCTOCS control arm participants which included serum samples up to two years before OC diagnosis. RESULTS: The cell-free DNA amount and average fragment size in the serum samples was up to ten times higher than average published values (based on samples that were immediately processed) due to leakage of DNA from white blood cells owing to delayed time to serum separation. Despite this, the marker panel discriminated high grade serous OC patients from healthy women or patients with a benign pelvic mass with specificity/sensitivity of 90.7% (95% confidence interval [CI] = 84.3-94.8%) and 41.4% (95% CI = 24.1-60.9%), respectively. Levels of all three markers plummeted after exposure to chemotherapy and correctly identified 78% and 86% responders and non-responders (Fisher's exact test, p = 0.04), respectively, which was superior to a CA125 cut-off of 35 IU/mL (20% and 75%). 57.9% (95% CI 34.0-78.9%) of women who developed OC within two years of sample collection were identified with a specificity of 88.1% (95% CI = 77.3-94.3%). Sensitivity and specificity improved further when specifically analyzing CA125 negative samples only (63.6% and 87.5%, respectively). CONCLUSIONS: Our data suggest that DNA methylation patterns in cell-free DNA have the potential to detect a proportion of OCs up to two years in advance of diagnosis and may potentially guide personalized treatment. The prospective use of novel collection vials, which stabilize blood cells and reduce background DNA contamination in serum/plasma samples, will facilitate clinical implementation of liquid biopsy analyses.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x krev $x genetika $x normy $7 D014408
650    _2
$a volné cirkulující nukleové kyseliny $x genetika $7 D000073888
650    12
$a metylace DNA $7 D019175
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádory vaječníků $x krev $x genetika $7 D010051
650    _2
$a náhodné rozdělení $7 D011897
650    _2
$a sekvenční analýza DNA $x metody $x normy $7 D017422
655    _2
$a hodnotící studie $7 D023362
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zikan, Michal $u Gynaecologic Oncology Center, Department of Obstetrics & Gynaecology, First Faculty of Medicine & General University Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Wahl, Benjamin $u GATC Biotech AG, Jakob-Stadler-Platz 7, 78467, Konstanz, Germany.
700    1_
$a Lempiäinen, Harri $u Genedata AG, Margarethenstrasse 38, 4053, Basel, Switzerland.
700    1_
$a Paprotka, Tobias $u GATC Biotech AG, Jakob-Stadler-Platz 7, 78467, Konstanz, Germany.
700    1_
$a Evans, Iona $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, Room 340, 74 Huntley Street, London, WC1E 6AU, UK.
700    1_
$a Jones, Allison $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, Room 340, 74 Huntley Street, London, WC1E 6AU, UK.
700    1_
$a Ghazali, Shohreh $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, Room 340, 74 Huntley Street, London, WC1E 6AU, UK.
700    1_
$a Reisel, Daniel $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, Room 340, 74 Huntley Street, London, WC1E 6AU, UK.
700    1_
$a Eichner, Johannes $u Genedata AG, Margarethenstrasse 38, 4053, Basel, Switzerland.
700    1_
$a Rujan, Tamas $u Genedata AG, Margarethenstrasse 38, 4053, Basel, Switzerland.
700    1_
$a Yang, Zhen $u CAS Max-Planck Partner Institute for Computational Biology, Shanghai Institute of Biological Sciences, 320 Yue Yang Road, Shanghai, 200031, China.
700    1_
$a Teschendorff, Andrew E $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, Room 340, 74 Huntley Street, London, WC1E 6AU, UK. CAS Max-Planck Partner Institute for Computational Biology, Shanghai Institute of Biological Sciences, 320 Yue Yang Road, Shanghai, 200031, China.
700    1_
$a Ryan, Andy $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, Room 340, 74 Huntley Street, London, WC1E 6AU, UK.
700    1_
$a Cibula, David $u Gynaecologic Oncology Center, Department of Obstetrics & Gynaecology, First Faculty of Medicine & General University Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Menon, Usha $u Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, Medical School Building, Room 340, 74 Huntley Street, London, WC1E 6AU, UK.
700    1_
$a Wittenberger, Timo $u Genedata AG, Margarethenstrasse 38, 4053, Basel, Switzerland.
773    0_
$w MED00174694 $t Genome medicine $x 1756-994X $g Roč. 9, č. 1 (2017), s. 116
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29268796 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190118124320 $b ABA008
999    __
$a ok $b bmc $g 1364974 $s 1039146
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 9 $c 1 $d 116 $e 20171222 $i 1756-994X $m Genome medicine $n Genome Med $x MED00174694
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace